JioCare — Strategic Decision Layers

For a 90-day sprint · 21 April 2026

1. Care model asset / delivery posture

What do we build, what do we partner for, what do we refuse to touch?

• Physical footprint. Own clinics / franchise / partner with existing clinic-and-hospital networks / zero physical. 30-40% of primary interactions may need an in-person clinical touch point.
• CHW cadre. Job description & training - data capture vs. clinical triage vs. navigation vs. sales. Own employed cadre / gig-platform model / outsourced third-party cadre. Ratio per 1,000 members?
• Diagnostics and labs. Own sample-collection and limited assays (for biobank control) vs. full outsource
• Pharmacy rail. Netmeds formally integrated as JioCare arm vs. arms-length partner.
• Hospital network. Preferred network at negotiated rates / exclusive carve-outs / agnostic navigation. Navigation thesis is cleaner if we are structurally independent of hospital ownership.

2. Data and tech stack

• Data quality: Gradation of quality from different sources
• Clinical AI : Time to build and go live?
• Model layer. Jio Brain / model-agnostic (Anthropic, OpenAI, open-weights) / both.
• EMR and clinical workflow. Build in-house/use existing vs. license. Likely forced to build given India landscape.
• Biobank infrastructure. Onshore storage vendor, centralized vs. distributed, LIMS choice, consent platform.
• Personal Agent. Lives in JioApp / standalone app / both.
• Research Trust tech separation. Separate legal entity, separate cloud tenancy, separate key custody - are we keeping the stateless-compute promise at the architecture level?

3. Business model - where does the margin sit

Four P\&Ls are on the table.

• Insurer P\&L - claims savings captured at Jio Allianz MLR improvement.
• Care-entity P\&L - subscription from members (primary care, longevity, premium navigation).
• Research Trust P\&L - pharma LOIs, biomarker licensing, data partnerships.
• Reliance group synergy - Jio ARPU uplift, Retail footfall, AJio health-adjacent cross-sell, Netmeds GMV.

Which two underwrite the plan, which two are upside?

4. Beachhead customer

Who is the first cohort the operating system is designed for?

• Urban full stack cardiometabolic 45–65, clinical-grade product at ₹3–4L/year.
• Urban 30–45 performance / longevity, consumer product at ₹75K–1.5L/year.
• Young gym-bundled wellness membership (low price, fast scale, weak data compounding).
• Reliance employees in Jamnagar (captive testbed - legitimate pilot or Potemkin?)
• Large-corporate group-health buyers (Mahindra, Tata, L\&T, and the Reliance group itself).
• HNW families buying longevity (highest revenue per head, longest data runway, thinnest narrative fit).
• Diaspora-adjacent (Gulf-resident Indians buying for parents in India).
• State / PMJAY-eligible partnership (narrative-defining, impossible to monetize in 3 years).
• Self-insured SME pool.

Underlying question: one beachhead, or a sequenced two-step (e.g. employer-groups for scale + urban-affluent-cardiometabolic for data depth)?

4. Geography and rollout

• Mumbai-only
• Jamnagar-as-captive-testbed

6. Partnership and ecosystem

• Jio Allianz positioning. Exclusive wrap vs. anchor-plus-open (Bajaj, Star, ICICI Lombard wraps allowed). Vertical insurer stack vs. horizontal platform.
• Pharma partners. Exclusive first-mover deals (deCODE–Amgen pattern) vs. non-exclusive portfolio.
• Academic anchor. Indian partner - AIIMS / PHFI / CCMB / NCBS. International - Broad / Sanger / UK Biobank.

7. Governance, structure, talent

• Legal structure. One entity vs. separate insurance / care / data-trust / research-trust entities with intercompany contracts. Material tax, regulatory, and exit-optionality consequences.
• Research Trust governance. Reliance-controlled board / majority-independent / Section 8 with scientific advisory committee. The Data Dividend narrative collapses if the Trust is perceived as a Reliance subsidiary.
• Clinician model. Salaried / partnership-track / franchise-equity / pure contract.
• Owner of the OS inside Reliance. Reports into MDA’s office directly / JFS / Jio Platforms / a new vertical.

8. What we explicitly will not do

Candidates to consider:

• We will not sell raw identified data to any party, ever.
• We will not take equity in hospitals we navigate members to.
• We will not operate as an insurer - we do not take the risk; we only improve it.
• We will not acquire members through MLM / referral-bounty / network-marketing patterns.
• We will not enter rural markets until Year X.
• We will not offer fertility, oncology, or mental health in scope until post-pilot.
• We will not commit to an exclusive pharma partner in the Y1-3 window.